Why Did 333D (ASX:T3D) Shares Surge 40% Today?

Sonal Goyal

30 October 2026 11:54 AM AEDT

Why Did 333D (ASX:T3D) Shares Surge 40% Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Shares were trading at $0.035, up 40.00%, during the Trading session on 30 October 2026.
Net operating cash outflow narrowed to $62,827 from $250,085 in the June 2026 quarter.
Cash and cash equivalents stood at $249,191 at 30 September 2026, with estimated funding of 3.97 quarters.

333D Ltd (ASX:T3D) shares traded at $0.035 during the trading session on 30 October 2026, rising 40.00%. Over the same session the S&P/ASX 200 (ASX:XJO) stood at 8,973.00, up 0.91% or 81.20 points at 11:15 am. 333D operates in digital asset creation, management and monetisation, with a focus on healthcare applications including DICOM-based medical imaging, AI-enabled file encoding and digital content for platforms and 3D printing. Its most recent update was the Appendix 4C and quarterly activities report for the quarter ended 30 September 2026, released on 29 October 2026, a day before the session, so this article does not link the two events.

Latest Development: Quarterly Cash Flow Report (29 October 2026)

The company reported cash receipts from customers of $639,558, compared with $820,670 in the June 2026 quarter. Total operating payments were $702,386, made up of product Manufacturing and operating costs of $387,094, staff costs of $24,078 and administration and corporate costs of $291,214. Net operating cash outflow fell to $62,827 from $250,085, an improvement of about 75 per cent. Interest received was $1.

The report links the lower spending to the completion of the FY2026 software development program and to moderating development expenditure. It states that the documents do not establish the allocation of individual September payments to particular projects.

Product and Digital Asset Activities

The company's proprietary clinical software program uses de-identified cone-beam CT imaging data for potential dental and maxillofacial applications. Completion of a model Training and evaluation milestone was recorded in the June 2026 quarter. The next step is pre-deployment optimisation and validation, after which the commercial potential can be assessed.

In digital asset management, the company continued to provide services and software development to customers. Its focus remains on the digital asset management strategy and healthcare-related software applications.

Sector Context

The company operates at the intersection of medical imaging software, applied artificial intelligence and digital content management. Demand in this area depends on regulatory pathways for clinical tools, the adoption of imaging workflows by healthcare providers and the spread of digital file formats across manufacturing and content platforms. The company's own disclosures describe these as the areas in which it is concentrating its activity.

Risks

Cash and cash equivalents fell to $249,191 at 30 September 2026 from $312,018 at 30 June 2026. The company reported no financing facilities and no financing cash flows for the quarter. Bitcoin held as a treasury asset is not included in the reported cash balance, and the report does not state its quantity or market value. Commercialisation of the clinical software program has not yet been assessed, and related party payments of $46,146 included $40,000 in director fees.

What Lies Ahead

The company has scheduled its Annual General Meeting for 27 November 2026 at 11:00 am Melbourne time, to be held virtually. The next milestone flagged for the clinical software is pre-deployment optimisation and validation, and the board has stated that it will continue to monitor cash requirements and discretionary expenditure.

Final Word

The 40 per cent move in 333D shares on 30 October 2026 took place alongside a Quarterly Report that showed lower operating cash outflow, a cash balance that declined over the quarter and funding estimated at just under four quarters. The company's next disclosures will show progress on the clinical software milestones and the cash position after the annual meeting.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.